Cytochrome P450 3A4 Inhibitors [MoA] class drugs

242 results

  • afinitor - everolimus tablet

    (Everolimus)
    Novartis Pharmaceuticals Corporation
    Afinitor treats advanced HR+/HER2- breast cancer (with exemestane), progressive neuroendocrine tumors (pancreatic, GI, or lung), advanced renal cell carcinoma, and tuberous sclerosis complex (TSC)-associated renal angiomyolipoma, SEGA, and partial-onset seizures in adults and pediatric patients.
    Medication Details
    Drug Interactions

  • akynzeo - netupitant and palonosetron capsule

    (Netupitant And Palonosetron)
    Helsinn Therapeutics (U.S.), Inc.
    AKYNZEO (palonosetron/netupitant) is used with dexamethasone in adults to prevent acute and delayed nausea and vomiting from cancer chemotherapy, including highly emetogenic regimens. Available as capsules for broad chemotherapy use and as an injection for highly emetogenic chemotherapy only.
    Medication Details
    Drug Interactions

  • aponvie - aprepitant emulsion

    (Aprepitant)
    Heron Therapeutics, Inc.
    Aponvie is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. It has not been studied for treatment of established nausea and vomiting.
    Medication Details
    Drug Interactions

  • balversa - erdafitinib tablet, film coated

    (Erdafitinib)
    Janssen Products Lp
    BALVERSA treats adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease progressed after at least one prior systemic therapy. Patient selection requires an FDA-approved companion diagnostic. Not recommended for patients eligible for PD-1/PD-L1 inhibitor therapy who have not yet received it.
    Medication Details
    Drug Interactions

  • brilinta - ticagrelor tablet

    (Ticagrelor)
    Astrazeneca Pharmaceuticals Lp
    Brilinta reduces the risk of cardiovascular death, heart attack, and stroke in patients with acute coronary syndrome or prior heart attack. It also lowers the risk of first heart attack or stroke in high-risk coronary artery disease patients, and reduces stroke risk after mild ischemic stroke or high-risk TIA.
    Medication Details
    Drug Interactions